Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer

Asian Journal of Andrology

Volumn 10, Issue 5, 2008, Pages 758-764

  Jia, Rui Peng ^a   Xu, Lu Wei ^a   Su, Qi ^a   Zhao, Jian Hua ^a   Li, Wen Cheng ^a   Wang, Feng ^a   Xu, Zheng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2; Epidermal growth factor receptor; Prostatic neoplasms

Indexed keywords

ANDROGEN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; POLYCLONAL ANTIBODY; PROSTAGLANDIN E2;

ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCUBATION TIME; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE SECTION; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; AGED, 80 AND OVER; ANDROGENS; CELL LINE, TUMOR; CULTURE MEDIA, SERUM-FREE; CYCLOOXYGENASE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 50149083062     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00423.x     Document Type: Article

References (25)

1. Matsuura H, Sakaue M, Subbaramaiah K, Kamitani H, Eling TE, Dannenberg AJ, et al. Regulation of cyclooxygenase-2 by interferon gammaand transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells: Role of mitogen-activated protein kinases. J Biol Chem 1999; 274: 29138-48.
2. Ohneseit PA, Krebiehl G, Dittmann K, Kehlbach R, Rodemann HP. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro. Radiother Oncol 2007; 82: 229-38.
3. Saha D, Datta PK, Sheng H, Morrow JD, Wada M, Moses HL, et al. Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta 1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia 1999; 1: 508-17.
4. Neeraja S, Ramakrishna B, Sreenath AS, Reddy GV, Reddy PR, Reddanna P. Novel functional association of rat testicular membrane-associated cytosolic glutathione S transferases and cyclooxygenase in vitro. Asian J Androl 2005; 7: 171-8.
5. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overpression of cyclooxygenase 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1999; 1438: 120-30.
6. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8: 289-93.
7. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005; 11: 6261-9.
8. Lin DW, Nelson PS. The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma. Clin Prostate Cancer 2003; 2: 119-26.
9. Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004; 171: S59-62.
10. Sooriakumaran P, Langley SE, Laing RW, Coley HM. COX-2 inhibition: A possible role in the management of prostate cancer? J Chemother 2007; 19: 21-32.
11. Liao Z, Mason KA, Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: Is there a role? Drugs 2007; 67: 821-845.
12. Rao DS, Gui D, Koski ME, Popoviciu LM, Wang H, Reiter RE, et al. An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer. Appl Immunohistochem Mol Morphol 2006; 14: 375-83.
13. Narayanan BA, Narayanan NK, Davis L, Nargi D. RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: Modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 2006; 5: 1117-25.
14. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002; 53: 232-40.
15. Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: A review. J Urol 2003; 169: 2352-9.
16. Di Lorenzo G, Tortora G, DArmiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen - independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-44.
17. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005; 4: 101-12.
18. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research 2004; 64: 7002-10.
19. Connolly JM, Rose DP. Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 1991; 19: 173-80.
20. Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 2006; 207: 261-70.
21. Soo R, Putti T, Tao Q, Goh BC, Lee KH, Kwok-Seng L, et al. Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression. Arch Otolaryngol Head Neck Surg 2005; 131: 147-52.
22. Kim GE, Kim YB, Cho NH, Chung HC, Pyo HR, Lee JD, et al. Synchronous co-expression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: A potential predictor of poor survival. Clin Cancer Res 2004; 10: 1366-74.
23. Richardson CM, Richardson D, Swinson DE, Swain WA, Cox G, O'Byrne KJ. Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer 2005; 48: 47-57.
24. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005; 4: 1448-55.
25. Zhang X, Neufeld AH. Signal transduction pathways for epidermal growth factor stimulated cyclooxygenase-2 induction in astrocytes. Exp Eye Res 2007; 85: 280-8.